Affordable Access

deepdyve-link
Publisher Website

Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Authors
  • Lange, Jane M1
  • Laviana, Aaron A2
  • Penson, David F3, 4
  • Lin, Daniel W5
  • Bill-Axelson, Anna6
  • Carlsson, Sigrid V7, 8, 9
  • Newcomb, Lisa F10
  • Trock, Bruce J11
  • Carter, H Ballentine12
  • Carroll, Peter R13
  • Cooperberg, Mathew R14
  • Cowan, Janet E15
  • Klotz, Laurence H16
  • Etzioni, Ruth B1, 17
  • 1 Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 2 Vanderbilt Center for Health Services Research, Vanderbilt University, Nashville, Tennessee.
  • 3 Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee.
  • 4 Department of Health Policy, Vanderbilt University, Nashville, Tennessee.
  • 5 Department of Urology, University of Washington, Seattle, Washington.
  • 6 Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. , (Sweden)
  • 7 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 8 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 9 Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. , (Sweden)
  • 10 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 11 Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland.
  • 12 Department of Urology, Johns Hopkins Medicine, Baltimore, Maryland.
  • 13 Department of Urology, University of California at San Francisco, San Francisco, California.
  • 14 Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
  • 15 Mission Bay Library, University of California at San Francisco, San Francisco, California.
  • 16 Department of Urology, University of Toronto, Toronto, Ontario, Canada. , (Canada)
  • 17 Department of Health Services, University of Washington, Seattle, Washington.
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 01, 2020
Volume
126
Issue
3
Pages
583–592
Identifiers
DOI: 10.1002/cncr.32557
PMID: 31639200
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Active surveillance (AS) is an accepted means of managing low-risk prostate cancer. Because of the rarity of downstream events, data from existing AS cohorts cannot yet address how differences in surveillance intensity affect metastasis and mortality. This study projected the comparative benefits of different AS schedules in men diagnosed with prostate cancer who had Gleason score (GS) ≤6 disease and risk profiles similar to those in North American AS cohorts. Times of GS upgrading were simulated based on AS data from the University of Toronto, Johns Hopkins University, the University of California at San Francisco, and the Canary Pass Active Surveillance Cohort. Times to metastasis and prostate cancer death, informed by models from the Scandinavian Prostate Cancer Group 4 trial, were projected under biopsy surveillance schedules ranging from watchful waiting to annual biopsies. Outcomes included the risk of metastasis, the risk of death, remaining life-years (LYs), and quality-adjusted LYs. Compared with watchful waiting, AS biopsies reduced the risk of prostate cancer metastasis and prostate cancer death at 20 years by 1.4% to 3.3% and 1.0% to 2.4%, respectively; and 5-year biopsies reduced the risk of metastasis and prostate cancer death by 1.0% to 2.4% and 0.6% to 1.6%, respectively. There was little difference between annual and 5-year biopsy schedules in terms of LYs (range of differences, 0.04-0.16 LYs) and quality-adjusted LYs (range of differences, -0.02 to 0.09 quality-adjusted LYs). Among men diagnosed with GS ≤6 prostate cancer, obtaining a biopsy every 3 or 4 years appears to be an acceptable alternative to more frequent biopsies. Reducing surveillance intensity for those who have a low risk of progression reduces the number of biopsies while preserving the benefit of more frequent schedules. © 2019 American Cancer Society.

Report this publication

Statistics

Seen <100 times